DSP-0390 is an oral inhibitor of emopamil binding protein (EBP). It effectively suppresses the EBP enzyme, which is involved in a critical late-stage step of cholesterol biosynthesis. By inhibiting the synthesis of new cholesterol, DSP-0390 selectively induces cytotoxicity in rapidly proliferating GBM cells. In human GBM xenograft models, DSP-0390 has demonstrated significant antitumor activity.